Geographic Atrophy

The first 6 patients in the study had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within 4 to 6 months post transplantation.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, presented available treatment options and what is coming down the pipeline for retinal conditions.

Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.

Results from a recent study led researchers to advise clinicians of the potential for dystrophies that mimic age-related macular degeneration and other atrophic macular pathologies to be incorrectly diagnosed, which can impact treatment.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

The company also reported a positive outcome of an analysis of masked data from its ongoing MAGNIFY Phase 2 trial for zervimesine in adults with GA.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

The potential gene therapy candidate is being evaluated for geographic atrophy.

From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.

This year was brimming with advancements in eye care.

The global survey revealed similar challenges for individuals with unilateral and bilateral geographic atrophy.

EnVision Summit optometry faculty Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Ashley Wallace-Tucker, OD, FAAO, FSLS, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.

A few optometrists share which innovations in optometry they were most excited about in 2024.

Brush up your geographic atrophy knowledge with our 2024 content highlights.

The organization will provide resources for spreading awareness and educating patients and care givers.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

The data showed a reduction in the GA lesion growth rate of 15.3% versus placebo from 6 to 24 months and a slowing in GA growth rate of 13.4% from baseline to 24 months.